Projects in progress

erstellt von Almut Scherer zuletzt verändert: 23.06.2016 16:40

Listed are research projects that use SCQM data

  • TofaSwiss - Baseline characteristics of RA patients treated with tofacitinib (Study lead: Diego Kyburz)
  • TofaSwiss - Real–world effectiveness of tofacitinib in RA patients (Study lead: Axel Finckh)
  • TofaSwiss - Real–world tolerability of tofacitinib in RA patients (Study lead: Jean Dudler)
  • Combining EUropean Registry data to investigate efficacy and toxicity of TNF inhibitor mOnotherapy versus combination therapy with methotrexate in Psoriatic Arthritis – EUROMPA (Study lead : Burkhard Möller)
  • Analysis of fine anti-citrullinated peptide antibody specificities, anti-carbamylated peptide antibodies and genetic characteristics in psoriatic arthritis patients (Study lead : Michael J. Nissen)  
  • Radiographic damage and disability in patients with RA in relation to disease duration: How are patients doing in the era of available biologic treatment? (Study lead: Katja Heiniger und Ruediger Mueller)
  • Dosage adjustment of anti-tumor necrosis factor-alpha inhibitors in axial spondyloarthritis (Study lead: Adrian Ciurea)
  • Does the type of TNF inhibitor switch (ETA-->MAB versus MAB-->ETA versus MAB-->MAB) influences treatment response to a second TNF inhibitor? (Study lead: Adrian Ciurea, accepted 22.11.2015)
  • Prevalence of CPDD detected in hand x-ray of ccp negative vs ccp positive RA patients in the SCQM-RA Cohort (Study lead: Giorgio Tamborrini)
  • Influence of fibromyalgia on disease activity, function and response to treatment with TNF inhibitors in axial spondyloarthritis (Study lead: Adrian Ciurea)
  • Impact of axial spondyloarthritis on work participation and the role of anti-TNF treatment (Study lead: Adrian Ciurea)
  • Multiple adjusted analysis of response to treatment in radiographic versus non-radiographic axial SpA (Study lead: Adrian Ciurea)
  • GetReal: Mathematical modelling to predict relative effectiveness of biological and nonbiological DMARDs in rheumatoid arthritis (Study lead: Axel Finckh)
  • Reproductive factors as predictors of disease progression in rheumatoid arthritis patients (Study lead: Deshiré Alpízar Rodríguez)
  • Health-related quality of life in Swiss SLE and RA patients (Study lead: Benjamin Chaigne)
  • Women with axial spondyloarthritis (Study lead: Adrian Ciurea)
  • Oral and parental methotrexate (MTX): Comparison in efficacy and safety with other DMARDs in patients with psoriatic arthritis (Study lead: Burkhard Möller)
  • Regular exercise and functional outcomes in axial spondyloarthritis (Study lead: Adrian Ciurea)
  • Anemia and perceived disease burden in axial spondyloarthritis (Study lead: Adrian Ciurea)
  • The role of sulfasalazine for peripheral arthritis in axial spondyloarthritis (Study lead: Adrian Ciurea)
  • The effect of body mass index on the course of disease activity in axial spondyloarthritis (Study lead: Adrian Ciurea)
  • Coxitis in axial spondyloarthritis: frequency, determinants and outcome of inflammatory and post-inflammatory hip involvement in the SCQM-axSpA cohort (Study lead: Adrian Ciurea)
  • Methotrexate and leflunomide in patients with rheumatoid arthritis: rates of and reasons for discontinuation (Study lead: Axel Finckh)
  • Hand osteoarthritis in the SCQM patient cohort (Study lead: Thomas Hügle, Ulrich Walker)
  • Clinical and ultrasound evolution after one year of patients considered at baseline in clinical remission according to the DAS or the new ACR/EULAR criteria (Study lead: Pascal Zufferey)
  • Analysis of fine ACPA specifities and genetic characteristics in RA patients (Study lead: Cem Gabay)
  • Impact of enthesitis on quality of life in spondyloarthritis patients; an analysis of the Swiss clinical quality management (SCQM) database (Study lead: Rüdiger Müller)
  • Effectiveness of sulfasalazine, leflunomide or ciclosporine in comparison to MTX as co-medication for newly established TNF antagonist treatment in psoriatic arthritis (Study lead: Rüdiger Müller)
  • Do cigarette smoking habits influence the likelihood of responding to rituximab treatment in RA patients? (Study lead: Saedis Saevarsdottir)
  • Prediction of erosions in RA by echographic signs of synovial hyperplasia and synovial hypervascularity (Study lead: Burkhard Möller)
  • How low should you go? Towards personalized treatment targets in RA. (Study lead: Diego Kyburz, Universitätsspital Zürich, and Jaap Fransen, Radboud University Nijmegen Medical Centre)
  • Do patients fulfilling the imaging-arm of the ASAS axial spondyloarthritis classification criteria differ from patients fulfilling the clinical-arm within the SCQM axial SpA cohort? (Study lead: Adrian Ciurea)
  • Diagnosis versus classification: Comparison of patients fulfilling the ASAS axial spondyloarthritis classification criteria and ASAS-negative patients in the SCQM axial SpA cohort (Study lead: Adrian Ciurea)
  • Gender differences in the SCQM axial SpA cohort (Study lead: Adrian Ciurea)
  • Improvement of the diagnostic delay in patients with axial spondyloarthritis (Study lead: Adrian Ciurea)
  • The prevalence of iron deficiency in RA - a cross sectional study (Study lead: Burkhard Möller)
  • Pan-European database analysis of Abatacept Effectiveness Data (Study lead: Axel Finkh)
  • Major cardiovascular events and their clinical and biological predictive markers in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis:  A Swiss Cohort Study (Study lead: Paola Chevallier). This study received the Abbott Price 2011. 
  • Are structural differences between anti-TNF agents associated with dissimilar rates of secondary loss of effectiveness and drug adjustments? (Study lead: Sophie Martin Du Pan and Axel Finckh)
  • The impact of statins on structural bone damage in rheumatoid arthritis (Study lead: Axel Finckh)
  • Predictors for duration of remission after discontinuation of biologics therapy (Study lead: Diego Kyburz).
  • Joint involvement in psoriatic arthritis: Application of the CASPAR classification criteria for PsA and changes in joint involvement over time. (Study lead: Burkhard Möller)
  • Determinants of radiographic progression over 4 years in the SCQM AS cohort (Study lead: Adian Ciurea).
  • Determinants of Fatigue and response to treatment in the practice-based Swiss prospective obserational cohort of axial SpA patients SCQM AS (Study lead: Pascale Exer & Ulrich Weber)
  • Frequency and determinants of osteoporosis in the practice-based Swiss prospective observational cohort of axial SpA patients SCQM AS (Study lead: Jürg Bernhard & Ulrich Weber)